Abstract:
An artificial mitral valve has a ring, an anterior cusp-side region, a posterior cusp-side region and a valve leaflet connected along an outer edge of the ring. The valve leaflet includes an anterior cusp forming member connected to the anterior cusp-side region and a posterior cusp forming member connected to the posterior cusp-side region. The anterior cusp forming member is provided with has an upper edge joined to the ring and a lower edge that forms a bifurcated portion. The upper edge is made up of a pair of right and left edges that incline inward and upward from the right and left sides, and a curved edge interposed between the inclined edges that curves along the anterior cusp-side region. The posterior cusp forming member has an upper edge joined to the ring and a lower edge that forms a bifurcated portion.
Abstract:
An artificial mitral valve has a ring, an anterior cusp-side region, a posterior cusp-side region and a valve leaflet connected along an outer edge of the ring. The valve leaflet includes an anterior cusp forming member connected to the anterior cusp-side region and a posterior cusp forming member connected to the posterior cusp-side region. The anterior cusp forming member is provided with has an upper edge joined to the ring and a lower edge that forms a bifurcated portion. The upper edge is made up of a pair of right and left edges that incline inward and upward from the right and left sides, and a curved edge interposed between the inclined edges that curves along the anterior cusp-side region. The posterior cusp forming member has an upper edge joined to the ring and a lower edge that forms a bifurcated portion.
Abstract:
The present invention suppresses the strength reduction or degeneration of a tissue after the tissue is dried and/or sterilized, for the tissue comprising biological components and the like. Specifically, biological tissue is immersed in a trehalose solution and shaken, thereby impregnating the biological tissue with the trehalose solution. The trehalose solution used here is one obtained by dissolving trehalose in a phosphate buffered saline, the concentration of trehalose being preferably in the range of 20 wt % to 35 wt %. Thereafter, the biological tissue is dried to remove moisture in the biological tissue, and sterilized with ethylene oxide gas.
Abstract:
The present invention suppresses the strength reduction or degeneration of a tissue after the tissue is dried and/or sterilized, for the tissue comprising biological components and the like. Specifically, biological tissue is immersed in a trehalose solution and shaken, thereby impregnating the biological tissue with the trehalose solution. The trehalose solution used here is one obtained by dissolving trehalose in a phosphate buffered saline, the concentration of trehalose being preferably in the range of 20 wt % to 35 wt %. Thereafter, the biological tissue is dried to remove moisture in the biological tissue, and sterilized with ethylene oxide gas.